Pemirolast Potassium

CHEMBL1201050 Phase 4 Zugelassen Small molecule
Half-Life
Bioavailability
Protein Binding
Molecular Weight
266.3 g/mol
LogP
Phase
4

A potassium salt form of pemirolast, sharing the same therapeutic uses.

Molekularmasse

266,3000 g/mol

TPSA

72,30 Ų

Therapeutische Bereiche

Pharmacokinetics (PK)

Pharmacodynamics (PD)

2D-Struktur

SVG PNG

Cite this structure


                        

Embed this structure


                        

SMILES

Cc1cccn2c(=O)c(-c3nnn[n-]3)cnc12.[K+]

InChI

InChI=1S/C10H7N6O.K/c1-6-3-2-4-16-9(6)11-5-7(10(16)17)8-12-14-15-13-8;/h2-5H,1H3;/q-1;+1

Molecular Formula

C10H7KN6O

HBD / HBA

- / 6

Rotierbare Bindungen

1

Schwere Atome

18

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Häufig gestellte Fragen

A potassium salt form of pemirolast, sharing the same therapeutic uses.

Yes, Pemirolast Potassium is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1201050. Open-access bioactivity database.
  • PubChem — National Center for Biotechnology Information (NCBI). CID 443866. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.

Medizinischer Haftungsausschluss

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.